Serina Therapeutics Inc (SER) AI Stock Analysis
SER AI stock analysis summary
AI ResearchSerina Therapeutics Inc is a clinical-stage biotechnology firm developing treatments for neurological diseases and pain management. The company reported trailing twelve month revenue of $0 and incurred a net loss of -$19.2M in FY2025 as research spending reached $13.2M. As of June 30, 2026, it held $23.0M in cash and short-term investments with a net cash position of $19.8M.
- Market cap
- $43.7M
- Revenue (TTM)
- $0
- P/E
- —
- 1Y return
- -64.8% S&P 500 16.8%
- Avg. target
- $9.50 452.3% vs last close
Bull case
- The consensus analyst price target of $9.50 represents an upside of 452.3% from the last close of $1.72.
- The balance sheet maintains liquidity with $23.0M in cash and short-term investments and a current ratio of 6.65 as of June 30, 2026.
- Company insiders maintain high alignment with outside investors, owning 50.8% of outstanding shares.
Bear case
- The company burned -$18.0M in free cash flow in FY2025 while generating $0 in revenue over the trailing twelve months.
- Substantial equity dilution has occurred, evidenced by a 1418.8% increase in share count over 5 years after $12.5M in share issuance in FY2025.
- The stock has declined 64.8% over the trailing 1-year period and trades 18.9% below its 200-day moving average.
What Serina Therapeutics does
Serina Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions for neurological diseases and pain management. Founded in 2006 and based in Huntsville, Alabama, its drug pipeline includes SER 252, a POZ conjugate targeting Parkinson's disease, alongside SER 214 for Parkinson's disease and SER 228 for epilepsy management. The company is also developing SER 227 for long-acting pain relief. Beyond these central nervous system indications, Serina is advancing POZ technology applications in lipid nanoparticle-delivered RNA vaccines targeting infectious diseases.
Growth and profitability
Serina's annual revenue has varied significantly, reporting $3.5M in FY2021, $500,000 in FY2022, and $3.2M in FY2023. Revenue fell to $56,000 in FY2024 before reaching $130,000 in FY2025, alongside an operating margin of -18478.5%. Net income declined from $5.3M in FY2023 to -$11.1M in FY2024 and -$19.2M in FY2025, driven by R&D expense rising to $13.2M. Over the trailing twelve months, revenue was $0 and EPS was -$1.87. In the latest quarter ended June 30, 2026, quarterly revenue increased 154.9% year-over-year, while quarterly earnings declined 43.5%.
Balance sheet and cash flow
As of June 30, 2026, Serina held $23.0M in cash and short-term investments against total debt of $3.2M, resulting in net cash of $19.8M and a current ratio of 6.65. Shareholders' equity stood at $18.7M with a debt-to-equity ratio of 0.17. In FY2025, operating cash flow was -$18.0M and free cash flow was -$18.0M, with capital expenditures of $59,000. Cash was supplemented by $12.5M in share issuance in FY2025, contributing to a 5-year share count increase of 1418.8%.
Valuation and performance
Serina has a market capitalization of $43.7M and an enterprise value of $35.8M. The stock trades at a price-to-sales multiple of 323.0x and an EV-to-EBITDA multiple of 37.4x, well above the medians of 4.1x and 12.0x, respectively, for its US-listed Healthcare peers. Its price-to-book ratio is 3.0x. The stock has dropped 64.8% over the past year and 94.8% over five years, underperforming the S&P 500, which gained 16.8% over one year and 83.0% over five years.
What analysts expect
Serina has 1 Strong Buy recommendation and zero Buy, Hold, or Sell ratings. The mean price target is $9.50, which stands 452.3% above the October 16, 2026 closing price of $1.72. For the fiscal year ending December 31, 2026, analysts forecast an EPS of -$1.58 on $0 revenue. For the following fiscal year, two analysts project an EPS of -$1.16 on $0 revenue. The company exceeded EPS expectations in 2 of the last 4 quarters, and its next earnings date is November 12, 2026.
Key risks and what to watch
- Annual free cash flow burn of -$18.0M in FY2025 threatens the current cash cushion of $23.0M reported at the end of June 30, 2026.
- Analyst forecasts project $0 in revenue for both FY2026 and the following fiscal year.
- Operating expenses remain substantial, with R&D spending climbing to $13.2M in FY2025.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this SER AI stock analysis
This page is an AI-written research summary of Serina Therapeutics Inc (SER). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: SER income statement, SER balance sheet, SER key metrics, SER analyst forecast, SER chart. See the SER stock overview for the latest quote and news.
SER AI stock analysis FAQ
What therapeutic areas does Serina Therapeutics target?
Serina Therapeutics develops treatments for neurological disorders and pain, with pipeline assets including SER 252 and SER 214 for Parkinson's disease, SER 227 for pain relief, and SER 228 for epilepsy.
How much cash does Serina Therapeutics have?
As of June 30, 2026, Serina held $23.0M in cash and short-term investments against $3.2M in total debt, leaving net cash of $19.8M.
What is the Wall Street analyst price target for SER stock?
Wall Street analysts have a mean price target of $9.50 for SER, reflecting a 452.3% premium relative to its closing price of $1.72 on October 16, 2026.
Does Serina Therapeutics pay a dividend?
Serina Therapeutics does not pay a dividend. The company directs its capital toward research and clinical development, posting an R&D expense of $13.2M in FY2025.